Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 12, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
On April 11, 2006, administrators notified the company of an increase in interests in Ordinary Share ADRs for specific individuals following the reinvestment of the dividend paid on April 6, 2006. The transaction price was $51.88 per ADR. The specific increases were:
- Dr F Calhoun: 49.549 ADRs
- Dr J P Garnier: 346.947 ADRs
- Mr D Phelan: 74.344 ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the dividend payment date of April 6, 2006, and the reinvestment mechanism for the Performance Share Plan.
- Confirm the ADR price of $51.88 on the transaction date.
- Review the total holdings of Dr F Calhoun, Dr J P Garnier, and Mr D Phelan to assess the significance of these incremental increases.